We have previously demonstrated that agmatine inhibited NF-κB signaling in the lungs and protected mice against Zymosan-induced acute lung injury, suggesting that agmatine may be a potential safe and effective approach for the treatment of acute lung injury [20]. Here, NFKB1 is linked to injury.